CR1 and cancer: Like all normal cells, cancer cells are protected from autologous complement attack by several specific cell-surface complement inhibitors: CD55 (decay accelerating factor, DAF), CD46 (membrane cofactor protein, MCP), CD59, and CD35 (complement receptor type 1, CR1) (1, 97–99) (Figure 1).